Table 1 Characteristics of the HCM Patient and Control Cohorts
From: Endogenous T1ρ cardiovascular magnetic resonance in hypertrophic cardiomyopathy
HCM patients (N = 40) | Healthy Controls (N = 10) | p-value | |
|---|---|---|---|
Age (years) | 50 [35, 57] | 51 [38, 55] | 1 |
Gender | 0.724 | ||
Male | 21 (52.5%) | 4 (40.0%) | |
Female | 19 (47.5%) | 6 (60.0%) | |
BSA (m2) | 2.0 [1.8, 2.2] | 1.8 [1.7, 2.1] | 0.254 |
Hematocrit (%) | 42.0 [39, 43.3] | 39.5 [37.0, 41.0] | 0.002 |
Medical history | |||
Coronary artery disease | 0 (0%) | ||
Hypertension | 16 (40.0%) | ||
Diabetes mellitus | 2 (5.0%) | ||
Stroke or transient ischemic attack | 0 (0%) | ||
Hospitalization for heart failure | 1 (2.5%) | ||
Ventricular arrhythmia | 12 (30.0%) | ||
Syncope | 6 (15.0%) | ||
Maximum LV wall thickness (mm) | 17.5 (3.25) | ||
LVOT obstruction | 14 (35.0%) | ||
Mitral regurgitation | |||
None | 5 (12.5%) | ||
Mild/trace | 27 (67.5%) | ||
Moderate | 5 (12.5%) | ||
Severe | 3 (7.5%) | ||
NYHA heart failure classification | |||
I | 19 (47.5%) | ||
II | 13 (32.5%) | ||
III | 8 (20.0%) | ||
IV | 0 (0%) | ||
ESC risk score (%) | 2.19 (0.924) | ||
Genotype positive | 10 (25.0%) | ||